





# SPOTLIGHT ON STAKEHOLDER SUCCESS

A noninvasive serologic model using an intelligent informatic solution to enhance clinical decision-making and improve patient safety

 <b>PATIENT</b>	<b>EARLIER DIAGNOSIS</b>	Of patients undergoing investigation for suspected primary hepatocellular carcinoma (HCC), an additional 17.4% (from 54.4% to 71.8%) were identified earlier using ASAP (age, sex, AFP, and PIVKA-II) (versus AFP alone), with subsequently confirmed pathological findings.
 <b>CLINICIAN</b>	<b>INCREASED CONFIDENCE</b>	Following a physician questionnaire, respondents indicated a 19.3% increase (from 74.0% to 93.3%) in added clinical confidence through use of the ASAP model in addition to other clinical information such as AFP and imaging, for the early screening, diagnosis and treatment of patients with liver cancer.
 <b>HEALTH SYSTEM / ADMINISTRATION</b>	<b>INCREASED REPUTATION</b>	A minimum of three earned honors across China as a direct consequence of this ASAP clinical care initiative: <ul style="list-style-type: none"><li>• 2021 Excellence Award of the Chinese Anti-Cancer Association</li><li>• 2021 Award for Excellent Case of Medical Laboratory Testing Branch of China Association of Medical Equipment</li><li>• Invited guest speaker on Chinese radio channel ('One Doctor in A Hundred' Show, Jilin Radio and TV Station) with audience over 710,000.</li></ul>
 <b>PAYOR</b>	<b>REDUCED HEALTHCARE COSTS</b>	Implementation of the ASAP risk model enabled a reduction in the number of unnecessary imaging examination, invasive procedures, and surgeries for patients, saving approximately ¥8,005 per patient (ranging from ¥200.0 to ¥25,801, with a median of ¥ 8,005).